Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABC008 |
Synonyms | |
Therapy Description |
ABC008 is a monoclonal antibody that targets KLRG1 expressed on CD8+ cytotoxic T-lymphocytes, which potentially leads to depletion of CD8+ T-lymphocytes (Annals of the Rheumatic Diseases 2022;81:1008-1009). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABC008 | ABC-008|ABC 008|ulviprubart | ABC008 is a monoclonal antibody that targets KLRG1 expressed on CD8+ cytotoxic T-lymphocytes, which potentially leads to depletion of CD8+ T-lymphocytes (Annals of the Rheumatic Diseases 2022;81:1008-1009). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05532722 | Phase Ib/II | ABC008 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | Active, not recruiting | USA | 0 |